CARA VS INCR Stock Comparison

Performance

CARA
10/100

CARA returned -89.02% in the last 12 months. Based on SPY's performance of -20.58%, its performance is below average giving it a score of 10 of 100.

INCR
10/100

INCR returned -78.13% in the last 12 months. Based on SPY's performance of -13.07%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

CARA
79/100

7 analysts offer 12-month price targets for CARA. Together, they have an average target of 28, the most optimistic target put CARA at 30 within 12-months and the most pessimistic has CARA at 26.

INCR
71/100

12 analysts offer 12-month price targets for INCR. Together, they have an average target of 0, the most optimistic target put INCR at 0 within 12-months and the most pessimistic has INCR at 0.

Sentiment

CARA
67/100

CARA had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 7.42 posts, 3.60 comments, and 9.03 likes per day.

INCR

"Sentiment" not found for INCR

Technicals

CARA
14/100

CARA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

INCR
43/100

INCR receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

CARA
10/100

CARA has missed earnings 6 times in the last 20 quarters.

INCR
10/100

INCR has missed earnings 5 times in the last 20 quarters.

Profit

CARA
10/100

Out of the last 20 quarters, CARA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

INCR
60/100

Out of the last 20 quarters, INCR has had 12 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

CARA
41/100

CARA has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

INCR
47/100

INCR has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Cara Therapeutics, Inc. Summary

Nasdaq / CARA

Healthcare

Biotechnology

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Intercure Ltd. Ordinary Shares Summary

Nasdaq / INCR

Healthcare

Drug Manufacturers - Specialty & Generic

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Power up your portfolio